T Rx Ade Health, Inc MEDS
We take great care to ensure that the data presented and summarized in this overview for TRxADE HEALTH, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MEDS
Top Purchases
Top Sells
About MEDS
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Insider Transactions at MEDS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2024
|
Surendra K Ajjarapu Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
150,000
+50.0%
|
-
|
|
Jan 05
2024
|
Prashant Patel Interim CFO and Director |
BUY
Grant, award, or other acquisition
|
Indirect |
150,000
+50.0%
|
-
|
|
Jan 16
2023
|
Michael L Peterson Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+45.67%
|
-
|
|
Dec 30
2022
|
A. Jeffrey Newell Director |
BUY
Grant, award, or other acquisition
|
Direct |
79,062
+50.0%
|
-
|
|
Dec 13
2022
|
Janet Huffman CFO, PAO, PFO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+41.14%
|
-
|
|
Sep 01
2022
|
Prashant Patel Interim CFO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,620
+0.68%
|
-
|
|
Sep 01
2022
|
Charles L Pope Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,525
+45.45%
|
-
|
|
Sep 01
2022
|
Janet Huffman CFO, PAO, PFO |
BUY
Grant, award, or other acquisition
|
Direct |
21,551
+50.0%
|
-
|
|
Sep 01
2022
|
Donald G. Fell Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,525
+41.88%
|
-
|
|
Sep 01
2022
|
Surendra K Ajjarapu Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
51,724
+4.25%
|
-
|
|
Aug 25
2022
|
Donald G. Fell Director |
BUY
Open market or private purchase
|
Direct |
1,500
+6.63%
|
$1,500
$1.08 P/Share
|
|
May 20
2022
|
Surendra K Ajjarapu Chairman and CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.3%
|
$130,000,000
$13000.0 P/Share
|
|
May 12
2022
|
Donald G. Fell Director |
BUY
Open market or private purchase
|
Direct |
2,000
+9.24%
|
$2,000
$1.26 P/Share
|
|
Jun 21
2021
|
Michael L Peterson Director |
SELL
Open market or private sale
|
Direct |
900
-14.32%
|
$3,600
$4.45 P/Share
|
|
May 27
2021
|
Christine L. Jennings Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,912
+50.0%
|
$32,736
$3.78 P/Share
|
|
May 27
2021
|
Michael L Peterson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,041
-56.12%
|
-
|
|
May 27
2021
|
Pamela Tenaerts |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,041
-42.53%
|
-
|
|
May 27
2021
|
Charles L Pope Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,912
+50.0%
|
$32,736
$3.78 P/Share
|
|
May 05
2021
|
Donald G. Fell Director |
SELL
Bona fide gift
|
Direct |
300
-1.67%
|
-
|
|
May 04
2021
|
Donald G. Fell Director |
SELL
Bona fide gift
|
Direct |
2,250
-11.14%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 300K shares |
|---|